Zymeworks Inc. (ZYME) NYSE
$12.40 0.22 (1.77%)
Market Cap: $880.63M
As of 09/13/24 11:54 AM EDT. Market open.
Zymeworks Inc. (ZYME)
NYSE
$12.40
0.22 (1.77%)
Market Cap: $880.63M
As of 09/13/24 11:54 AM EDT. Market open.
Add to Portfolio
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a ... read more
COMPANY PROFILE
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Kenneth H. Galbraith C.A.
Full Time Employees
290
CEO Compensation (Base)
$105,742
CEO Compensation (Total)
$964,243
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Kenneth H. Galbraith C.A.
Full Time Employees
290
CEO Compensation (Base)
$105,742
CEO Compensation (Total)
$964,243
Address
114 East 4th Avenue, BC, Vancouver, V5T 1G4.
PRICE CHART FOR ZYMEWORKS INC.
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$12.23
Previous Close
$12.18
Days Range
$12.20 - $12.44
52 week range
$6.02 - $13.14
Volume
106,623
Avg. Volume (30 days)
684,127
Market Cap
$880.63M
Dividend Yield
-
P/E
(8.26)
Shares Outstanding
71,047,400
Open
$12.23
Previous Close
$12.18
Days Range
$12.20 - $12.44
52 week range
$6.02 - $13.14
Volume
106,623
Avg. Volume (30 days)
684,127
Market Cap
$880.63M
Dividend Yield
-
P/E
(8.26)
Shares Outstanding
71,047,400
FINANCIAL STATEMENTS FOR ZYMEWORKS INC.
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR ZYMEWORKS INC.
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Galbraith Kenneth | Chair & CEO | Jan 08, 2024 | Sale | $11.22 | 5,706 | 63,996 | 23,762 | Jan 08, 2024, 06:23 PM |
| Galbraith Kenneth | Chair & CEO | Jan 05, 2024 | Sale | $10.65 | 18,198 | 193,849 | 29,468 | Jan 08, 2024, 06:23 PM |
| Astle Christopher | SVP & Chief Financial Officer | Jan 08, 2024 | Sale | $11.22 | 1,431 | 16,050 | 6,503 | Jan 08, 2024, 06:14 PM |
| Astle Christopher | SVP & Chief Financial Officer | Jan 05, 2024 | Sale | $10.65 | 4,563 | 48,606 | 7,934 | Jan 08, 2024, 06:14 PM |
| Moore Paul Andrew | Chief Scientific Officer | Jan 08, 2024 | Sale | $11.22 | 2,339 | 26,233 | 7,367 | Jan 08, 2024, 06:01 PM |
| Moore Paul Andrew | Chief Scientific Officer | Jan 05, 2024 | Sale | $10.65 | 7,460 | 79,465 | 9,706 | Jan 08, 2024, 06:01 PM |
| Astle Christopher | SVP & Chief Financial Officer | Dec 11, 2023 | Sale | $9.13 | 886 | 8,089 | 1,997 | Dec 11, 2023, 08:00 PM |
| EcoR1 Capital, LLC | 10% Owner | Jun 16, 2023 | Buy | $8.12 | 3,350,000 | 27,202,000 | 13,437,473 | Jun 21, 2023, 04:04 PM |
| EcoR1 Capital, LLC | 10% Owner | Mar 28, 2023 | Buy | $8.00 | 200,000 | 1,600,000 | 10,087,473 | Mar 30, 2023, 05:47 PM |
| Klompas Neil A | President & COO | Mar 10, 2023 | Sale | $7.83 | 2,977 | 23,298 | 17,032 | Mar 14, 2023, 05:00 PM |
| EcoR1 Capital, LLC | 10% Owner | Jan 19, 2023 | Buy | $9.49 | 144,100 | 1,367,639 | 9,724,073 | Jan 23, 2023, 06:00 PM |
| EcoR1 Capital, LLC | 10% Owner | Jan 20, 2023 | Buy | $9.88 | 163,400 | 1,615,095 | 9,887,473 | Jan 23, 2023, 06:00 PM |
| EcoR1 Capital, LLC | 10% Owner | Jan 18, 2023 | Buy | $10.00 | 203,000 | 2,029,046 | 9,579,973 | Jan 18, 2023, 06:27 PM |
| EcoR1 Capital, LLC | 10% Owner | Jan 17, 2023 | Buy | $9.80 | 440,000 | 4,313,848 | 9,376,973 | Jan 18, 2023, 06:27 PM |
| EcoR1 Capital, LLC | 10% Owner | Jan 13, 2023 | Buy | $9.81 | 342,100 | 3,354,633 | 8,936,973 | Jan 18, 2023, 06:27 PM |
| EcoR1 Capital, LLC | 10% Owner | Jan 11, 2023 | Buy | $7.87 | 106,300 | 836,911 | 8,594,873 | Jan 12, 2023, 04:47 PM |
| EcoR1 Capital, LLC | 10% Owner | Jan 10, 2023 | Buy | $7.65 | 920,000 | 7,037,172 | 8,488,573 | Jan 12, 2023, 04:47 PM |
| Astle Christopher | SVP & Chief Financial Officer | Dec 12, 2022 | Sale | $6.01 | 887 | 5,331 | 1,333 | Dec 23, 2022, 08:00 PM |
| Josephson Neil | Chief Medical Officer | Nov 10, 2022 | Sale | $8.10 | 2,475 | 20,045 | 14,449 | Dec 23, 2022, 08:00 PM |
| Astle Christopher | SVP & Chief Financial Officer | Dec 12, 2022 | Sale | $6.01 | 887 | 5,331 | 1,333 | Dec 14, 2022, 08:00 PM |
| Josephson Neil | Chief Medical Officer | Nov 10, 2022 | Sale | $8.10 | 2,475 | 20,045 | 14,449 | Nov 14, 2022, 09:41 PM |
| Redmile Group, LLC | 10% Owner | Oct 13, 2022 | Buy | $5.03 | 30,481 | 153,435 | 6,075,918 | Oct 18, 2022, 06:07 AM |
| Redmile Group, LLC | 10% Owner | Oct 13, 2022 | Option Exercise | $5.03 | 30,481 | 153,435 | 6,075,918 | Oct 17, 2022, 09:48 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Galbraith Kenneth | Chair & CEO | 01/08/2024 | 63,996 |
| Galbraith Kenneth | Chair & CEO | 01/05/2024 | 193,849 |
| Astle Christopher | SVP & Chief Financial Officer | 01/08/2024 | 16,050 |
| Astle Christopher | SVP & Chief Financial Officer | 01/05/2024 | 48,606 |
| Moore Paul Andrew | Chief Scientific Officer | 01/08/2024 | 26,233 |
| Moore Paul Andrew | Chief Scientific Officer | 01/05/2024 | 79,465 |
| Astle Christopher | SVP & Chief Financial Officer | 12/11/2023 | 8,089 |
| EcoR1 Capital, LLC | 10% Owner | 06/16/2023 | 27,202,000 |
| EcoR1 Capital, LLC | 10% Owner | 03/28/2023 | 1,600,000 |
| Klompas Neil A | President & COO | 03/10/2023 | 23,298 |
| EcoR1 Capital, LLC | 10% Owner | 01/19/2023 | 1,367,639 |
| EcoR1 Capital, LLC | 10% Owner | 01/20/2023 | 1,615,095 |
| EcoR1 Capital, LLC | 10% Owner | 01/18/2023 | 2,029,046 |
| EcoR1 Capital, LLC | 10% Owner | 01/17/2023 | 4,313,848 |
| EcoR1 Capital, LLC | 10% Owner | 01/13/2023 | 3,354,633 |
| EcoR1 Capital, LLC | 10% Owner | 01/11/2023 | 836,911 |
| EcoR1 Capital, LLC | 10% Owner | 01/10/2023 | 7,037,172 |
| Astle Christopher | SVP & Chief Financial Officer | 12/12/2022 | 5,331 |
| Josephson Neil | Chief Medical Officer | 11/10/2022 | 20,045 |
| Astle Christopher | SVP & Chief Financial Officer | 12/12/2022 | 5,331 |
| Josephson Neil | Chief Medical Officer | 11/10/2022 | 20,045 |
| Redmile Group, LLC | 10% Owner | 10/13/2022 | 153,435 |
| Redmile Group, LLC | 10% Owner | 10/13/2022 | 153,435 |
Load More Insider Transactions
FUNDS WITH A POSITION IN ZYMEWORKS INC.
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| BLACKROCK INC. | 4,193,576 | 0.00081% | 2.39% | Other |
| FARALLON CAPITAL MANAGEMENT LLC | 1,601,000 | 0.06% | No change | Event Driven, Value |
| GEODE CAPITAL MANAGEMENT, LLC | 712,950 | 0.00053% | 6.57% | Other |
| AQR CAPITAL MANAGEMENT LLC | 94,272 | 0.00123% | -80.74% | Other |
| PLATINUM INVESTMENT MANAGEMENT LTD | 373,002 | 0.13% | -10.85% | Growth At A Reasonable Price, Value |
| RENAISSANCE TECHNOLOGIES LLC | 236,781 | 0.00342% | 104.83% | Other |
| FISHER ASSET MANAGEMENT, LLC | 63,600 | 0.00024% | New | Other |
| OCONNOR, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS (LLC) | 54,457 | 0.04% | Exited | Value |
| D. E. SHAW & CO., INC. | 43,756 | 0.00035% | 61.38% | Other |
| ALPS ADVISORS INC | 31,277 | 0.00183% | -0.52% | Other |
CHANGE IN SHARES OUTSTANDING FOR ZYMEWORKS INC.
STOCK BUYBACKS FOR ZYMEWORKS INC.
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 06/30/2024
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
03/31/2024
0.19%
1Q
12/31/2023
7.89%
2Q
09/30/2023
8.25%
3Q
06/30/2023
13.54%
4Q
03/31/2023
14.46%
5Q
12/31/2022
14.49%
6Q
09/30/2022
14.92%
7Q
06/30/2022
15.13%
8Q
03/31/2022
24.47%
9Q
12/31/2021
46.50%
10Q
09/30/2021
46.24%
11Q
06/30/2021
48.57%
12Q
03/31/2021
48.72%
13Q
12/31/2020
49.38%
14Q
09/30/2020
50.08%
15Q
06/30/2020
50.42%
16Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR ZYMEWORKS INC.
LOADING...